AstraZeneca (AZN LN) Q1 2026 (USD): Revenue 15.3bln (exp. 14.9bln), adj. EPS 2.58 (exp. 2.55). Confirms guidance for FY26. "...remain on track to achieve our ambition for 2030 and beyond."
Importance
Level 1
2026 Guidance (reconfirmed)
- Total Revenue is expected to increase by a mid-to-high single-digit percentage
- Core EPS is expected to increase by a low double-digit percentage